Episode Details

Morris Shannon, Erascas CMO, sold twenty thousand shares, netting $301,000, after exercising options. This was her first open-market sale under a pre-arranged plan, leaving her with zero direct shares. Despite this, she retains options for over five hundred thousand more shares. Erasca, focusing on precision cancer therapies, has seen its stock surge 924% over the past year, with a market cap of $4.71 billion. Investors view this as standard insider activity, given the companys strong momentum in oncology innovation.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/caf3f38fb2b23908